



Evidence-based Comparison of the
Synovasure[®] Alpha Defensin ELISA Test
and **Alpha Defensin Lateral Flow Test**

Overview:

Alpha defensin biomarker testing is the first test specifically designed and validated for use, as an adjunct to additional tests, in the diagnosis of periprosthetic joint infection (PJI). The test detects human alpha defensins in the synovial fluid of persons with a total joint replacement. Alpha defensins are antimicrobial peptides released by activated neutrophils in response to infection. There are two test options available: an ELISA test (available via laboratory) and a lateral flow device.

Synovasure Alpha Defensin ELISA Test

Synovasure Alpha Defensin ELISA test is a validated laboratory service performed by trained personnel in a certified laboratory (ie. CLIA (US), DAkkS (Germany), UKAS (UK)) with, typically, a 24–48 hours result turnaround. The Synovasure Alpha Defensin ELISA test is available in the US via CD Laboratories and in the EU via partner labs, the Fenner lab (Germany) and Golden Jubilee National Laboratory (UK).

Synovasure Alpha Defensin Lateral Flow Test

Synovasure Alpha Defensin Lateral Flow Test utilizes the same anti-microbial peptide to detect the immune response to infection as the ELISA test, but returns results in 10 minutes. The Synovasure Alpha Defensin Lateral Flow Test is available for use in numerous countries throughout the world.

Clinical Validation

In numerous clinical studies, both Synovasure Alpha Defensin test options demonstrated high levels of clinical performance through high sensitivity and specificity (see data table below).

Synovasure Alpha Defensin ELISA Test

| Study | N | Sensitivity | Specificity |
|---|------------|----------------------|----------------------|
| Rothman Institute ¹ | 149 | 97% (36/37) | 96% (107/112) |
| Mayo Clinic ² | 61 | 100% (19/19) | 95% (40/42) |
| Cleveland Clinic ³ | 78 | 100% (24/24) | 98% (53/54) |
| Endo Klinik ⁴ | 156 | 97% (28/29) | 97% (123/127) |
| Cleveland Florida ⁵ | 70 | 97% (34/35) | 97% (34/35) |
| Charite – Universitätsmedizin Berlin ⁶ | 71 | 85% (11/13)* | 98% (57/58) |
| Multi-center Study ^{7**} | 369 | 93% (113/122) | 98% (241/247) |
| Combined | 954 | 95% (265/279) | 97% (655/675) |

Synovasure Alpha Defensin Lateral Flow

| Study | N | Sensitivity | Specificity |
|-----------------------------------|-----|---------------|-----------------|
| Multi-center Study ^{7**} | 288 | 94.3% (50/53) | 94.5% (222/235) |

⊖ **Note:** Excludes samples with >20% blood

* Includes patients with a draining sinus

** Mayo Clinic, Cleveland Clinic – Florida, Sinai Hospital of Baltimore

Lateral Flow Studies: Understanding the Differences

Several studies have been published that assess the performance of the Synovasure Alpha Defensin Lateral Flow device. A number of factors can influence the performance and results of these studies; e.g.

- Using small sample sizes especially with low numbers of PJI positives⁸⁻¹⁰ can misrepresent performance of the test
- Potential misuse of LF device such as improper dilution of samples⁸ - user should always follow the manufacturer's instructions for use
- Use of criteria different from MSIS as the reference method
- Inclusion of joints with spacers⁹

ELISA Test vs. Lateral Flow Test

In a multi-center prospective clinical study, no statistically significant difference was shown between Synovasure Alpha Defensin ELISA Test and Synovasure Alpha Defensin Lateral Flow Test.⁷

Furthermore, two recently published clinical studies performed a comparison between the tests:

- Gehrke, *et al.*, demonstrated a 94.8% accuracy between the ELISA and Lateral Flow Test.¹¹
- Balato, *et al.*, concluded that "The diagnostic accuracy of the two alpha-defensin assessment methods is comparable".¹²

The Synovasure Alpha Defensin ELISA Test and the Synovasure Alpha Defensin Lateral Flow Test perform nearly equivalent with no statistically significant difference. The tests achieve a sensitivity and specificity of 94% or greater, which can be seen from the clinical studies for both.

References

1. Deirmengian CA, et al. Combined Measurement of Synovial Fluid α -Defensin and C-Reactive Protein Levels: Highly Accurate for Diagnosing Periprosthetic Joint Infection. *Journal of Bone and Joint Surgery Am.* 96(17):1439-45, 2014.
2. Bingham J., et al. The alpha Defensin-1 Biomarker Assay can be Used to Evaluate the Potentially Infected Total Joint Arthroplasty. *Clinical Orthopaedics and Related Research.* DOI 10.1007/s11999-014-3900-7 Sep. 26, 2014t.
3. Frangiamore S., et al. α -Defensin Accuracy to Diagnose Periprosthetic Joint Infection – Best Available Test? *Journal of Arthroplasty.* 312:456-60, 2016.
4. Bonazinga T., et al. How Reliable Is the Alpha-defensin Immunoassay Test for Diagnosing Periprosthetic Joint Infection? A Prospective Study. *Clinical Orthopaedics and Related Research.* DOI 10.1007/s11999-016-4906-0 75:408-15, 2017.
5. Kanwar S., et al. What is the optimal criteria to use for detecting periprosthetic joint infections before total joint arthroplasty? *Journal of Arthroplasty.* 33:S201e4, 2018.
6. Sigmund I., et al. Is the Enzyme-linked Immunosorbent Assay More Accurate Than the Lateral Flow Alpha Defensin Test for Diagnosing Periprosthetic Joint Infection? *Clinical Orthopaedics and Related Research.* 476:1645-54, 2018.
7. CDD-CLI-001: Clinical Validation of CD Diagnostics Synovasure PJI ELISA Test and Synovasure PJI Lateral Flow Test for Detection of Periprosthetic Joint Infection (PJI) in Synovial Fluid. Feb. 27, 2019.
8. Kasparek MF, et al. Intraoperative Diagnosis of Periprosthetic Joint Infection Using a Novel Alpha-Defensin Lateral Flow Assay. *Journal of Arthroplasty.* 31(12):2871- 74, 2016.
9. Sigmund IK, et al. Qualitative α -defensin test (Synovasure) for the diagnosis of periprosthetic infection in revision total joint arthroplasty. *Bone & Joint Journal.* 99-B(1):66-72, 2017.
10. Suda AJ, et al. Diagnosis of periprosthetic joint infection using alpha-defensin test or multiplex-PCR: ideal diagnostic test still not found. *International Orthopaedics.* 41(7):1307-13, 2017.
11. Gehrke T., et al. The Accuracy of the Alpha Defensin Lateral Flow Device for Diagnosis of Periprosthetic Joint Infection. *Journal of Bone and Joint Surgery Am.* 100(1):42-48, 2018.
12. Balato G., et al. Laboratory-based versus qualitative assessment of alpha-defensin in periprosthetic hip and knee infection: a systematic review and meta-analysis. *Archives of Orthopaedic and Trauma Surgery.* Jul. 12, 2019.

All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.

This material is intended for health care professionals. Distribution to any other recipient is prohibited.

For indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert or contact your local representative; visit www.zimmerbiomet.com for additional product information.

Not for distribution in France.

Check for country product clearances and reference product specific instructions for use.

© 2019 Zimmer Biomet



Authorized Representative

Zimmer GmbH
Sulzeralle 8
8404 Winterthur
Switzerland
USA



ZIMMER BIOMET

Your progress. Our promise.®

2377.1-GLBL-en-REV1019



Legal Manufacturer

CD Diagnostics
650 Naamans Rd, Suite 100
Claymont, DE 19711
USA

zimmerbiomet.com